Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

19 September 2024 : Clinical Research  

Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Sukunya Jirachaipitak1ABCDEF, Pramote Euasobhon1ABCDEFG*, Suthanee Cenpakdee1ABEF, Suratsawadee Wangnamthip1ABDE, Pranee Rushatamukayanunt1ABDE

DOI: 10.12659/MSM.945612

Med Sci Monit 2024; 30:e945612

Table 1 Demographic data. The data are presented as mean±standard deviation, number (%), or median (min–max).

CharacteristicsN=32
Sex
 Male21 (65.6)
 Female11 (34.4)
Age (year)43.6±14.8
Body mass index (kg/m)22.5±4.2
Initial NRS7 (4–10)
DN47 (0–10)
Maximal effective dose of oxcarbazepine (mg)1800 (600–1800)
 Peripheral nerve injury20 (62.5)
 Radicular pain3 (9.4)
 Spinal cord injury3 (9.4)
 Postherpetic neuralgia2 (6.3)
 Phantom limb pain2 (6.3)
 Postsurgical pain syndrome1 (3.1)
 Trigeminal neuralgia1 (3.1)
 Upper extremities19 (59.4)
 Lower extremities6 (18.8)
 Head3 (9.4)
 Upper body2 (6.3)
 Lower body2 (6.3)
NRS – numeric resting scale 0–10; DN-4 – Douleur Neuropathique 4 questionnaire.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750